Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTMEA-RWS: Trelagliptin Add-on to Metformin + Empagliflozin in Elderly Chinese Patients with Type 2 Diabetes Mellitus
ChiCTR2600116423Phase 4Not yet recruiting
- Sponsor
- Zhengzhou Central Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of trelagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Zhengzhou Central Hospital. Primary endpoint: HbA1c at week 12. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
trelagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2600116423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116423.